Recycling N-acetylcysteine: A review of evidence for adjunctive therapy in schizophrenia

firemonkey · May 28, 2019, 7:49pm

ncbi.nlm.nih.gov

Recycling N-acetylcysteine: A review of evidence for adjunctive therapy in schizophrenia.

RJ Willborn, CP Hall and MA Fuller, The mental health clinician, May 2019

All symptoms in schizophrenia may impact functioning. Although Food and Drug Administration-approved medications typically benefit positive symptoms, negative symptoms are generally refractory to medication interventions. N-acetylcysteine's (NAC) influence on glutamatergic neurotransmission has been established. An emerging body of research has attempted to correlate this action with reduction in symptom severity, evaluating response in positive, negative, and cognitive symptom domains.A literature review was performed to analyze available data on NAC intervention and improvement in the positive, negative, and cognitive symptom domains in patients with schizophrenia. Quality of evidence was systematically assessed to determine level of certainty in results.Three randomized controlled trials were identified. Across studies, negative symptoms decreased more with NAC compared to placebo; ranging between 11.9% and 24.1%. The assessment determined a low level of certainty regarding benefit of NAC on negative and cognitive symptoms and moderate certainty for NAC regarding findings of side effects and lack of benefit on positive symptoms.Consistent reporting of benefit in negative symptoms is found across studies of NAC intervention. These improvements are notable for symptoms that have generally remained refractory to medication intervention. Inconsistent benefit was reported in positive and cognitive symptoms. GRADE (grading of recommendations assessment, development and evaluation) assessment of current evidence indicates a low certainty of benefit for negative symptoms with standard use of NAC in patients with schizophrenia. However, a trial of this low-risk intervention may be warranted in patients with resistant negative symptoms and subsequent impaired functioning despite appropriate antipsychotic therapy as they may experience additional benefit in this symptom domain.

everhopeful · May 28, 2019, 8:35pm

I think NAC interacts with abilify to make it less effective. As a result It gave me suicidal ideation and also decreased the muscle stiffness associated with abilify.

Topic		Replies	Views
Antioxidant N-acetylcysteine (NAC) Effective in Treating Schizophrenia - Show Placebo-controlled Studies News	1	790	August 5, 2016
Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial News	6	2490	November 12, 2017
Given up on sarcosine and NAC Medications	8	2032	February 6, 2018
Supplements for Positive Symptoms Health and Recovery	4	1528	October 15, 2016
Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia News	0	284	December 13, 2019

Recycling N-acetylcysteine: A review of evidence for adjunctive therapy in schizophrenia

Related topics